Want to see SG:8YY full AI Analyst Report?
Biolidics Ltd. (8YY) AI Stock Analysis
Biolidics Ltd.
(SGX:8YY)
The score is held down primarily by weak financial performance (persistent losses, negative free cash flow, and a limited equity cushion relative to debt), alongside bearish technicals (price below all key moving averages and negative MACD). Valuation provides only modest support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Biolidics Ltd. (8YY) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- SGD 41.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 511.95K
- Price to Earnings (P/E)
- -12.6
- Beta (1Y)
- 0.45
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Singapore
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Biolidics Ltd. Business Overview & Revenue Model
Company Description
Embracing Future Holdings Limited, a Singapore-based medical technology firm, specializes in precision medicine, focusing on developing diagnostic solutions. Operating across Japan, Hong Kong, Thailand, Malaysia, and the United States, its business i...
How the Company Makes Money
Biolidics makes money primarily by selling diagnostic products and related solutions to customers such as clinical laboratories, hospitals, research institutions, and other healthcare or life-sciences users. Revenue is typically generated from (i) pr...
Biolidics Ltd. Financial Statement Overview
Summary
Despite a sharp 2025 revenue rebound (~+197% to ~5.3m), the company remains consistently loss-making with negative operating profit and net income (e.g., ~4.0m net loss in 2025). Cash generation is also weak with negative operating cash flow/free cash flow across the period (2025 FCF ~-0.36m). The balance sheet adds risk due to meaningful leverage versus a modest equity base (~2.4m debt vs ~1.5m equity in 2025) and a history of negative equity (2022–2023).
Income Statement
28NegativeBalance Sheet
34NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.82M | 5.26M | 784.00K | 277.00K | 2.49M | 2.31M |
| Gross Profit | 2.09M | 1.94M | 187.00K | 146.00K | 1.16M | 483.00K |
| EBITDA | -2.63M | -3.65M | -3.03M | -1.16M | -8.50M | -4.58M |
| Net Income | -3.05M | -3.96M | -3.43M | -2.49M | -9.37M | -5.98M |
Balance Sheet | ||||||
| Total Assets | 5.59M | 5.08M | 4.67M | 682.00K | 6.09M | 11.42M |
| Cash, Cash Equivalents and Short-Term Investments | 494.00K | 557.00K | 295.00K | 183.00K | 5.03M | 3.96M |
| Total Debt | 2.77M | 2.41M | 1.75M | 2.02M | 3.01M | 4.25M |
| Total Liabilities | 3.77M | 3.56M | 2.94M | 2.67M | 7.78M | 9.09M |
| Stockholders Equity | 1.83M | 1.53M | 1.73M | -1.99M | -1.69M | 2.33M |
Cash Flow | ||||||
| Free Cash Flow | 391.00K | -360.00K | -2.32M | -1.97M | -3.16M | -5.20M |
| Operating Cash Flow | 393.00K | -360.00K | -2.31M | -1.97M | -3.06M | -4.64M |
| Investing Cash Flow | -2,000 | 0 | -5,000 | -2.69M | 5,000 | -860.00K |
| Financing Cash Flow | -210.00K | 623.00K | 2.36M | -200.00K | 4.18M | -1.15M |
Biolidics Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 35.07 is Neutral, neither overbought nor oversold. The STOCH value of 39.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8YY.
Biolidics Ltd. Peers Comparison
Overall Rating
SG:P8A42Neutral- SG:8YY40Underperform
SG:9G238Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SG:P8A | 42Neutral | SGD 23.23M | -2.18 | -10.28% | ― | ― | ― |
| SG:8YY | 40Underperform | SGD 41.60M | -12.63 | -181.49% | ― | ― | ― |
| SG:9G2 | 38Underperform | SGD 39.65M | -0.72 | -73.80% | ― | -1.27% | 16.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:8YY | Biolidics Ltd. | 0.02 | 0.00 | 4.35% | |
| SG:P8A | Cordlife Group | 0.09 | -0.07 | -43.13% | |
| SG:40T | ISEC Healthcare Ltd | 0.31 | -0.02 | -6.91% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.10 | -0.02 | -18.40% | |
| SG:584 | AJJ Medtech Holdings Limited | 0.01 | 0.00 | 0.00% | |
| SG:9G2 | Singapore Institute of Advanced Medicine Holdings Ltd. | 0.02 | -0.01 | -28.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026